Lymphangiogenesis in Non-Hodgkin's Lymphoma and Its Correlation with Cyclooxygenase-2 and Vascular Endothelial Growth Factor-C

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Dec 4

PMID 23205085

Citations 7

Authors

Shu-Pei Ma

Mei Lin

Hai-Ning Liu

Jian-Xian Yu

Affiliations

Soon will be listed here.

Abstract

We aimed to investigate the correlations between lymphangiogenesis, cyclooxygenase (COX)-2 and vascular endothelial growth factor-C (VEGF-C) in non-Hodgkin's lymphoma (NHL) and their associations with the clinical parameters of patients. A total of 75 patients diagnosed with NHL were enrolled in this study. Of the 75 patients, 14 (18.7%) had low-grade and 61 (81.3%) had aggressive lymphoma. We examined the immunohistochemical expression of COX-2 and VEGF-C and estimated lymphangiogenesis by counting lymphatic vessels expressing lymph vessel endothelial hyaluronan receptor-1 (LYVE-1). Our results showed that lymphatic vessel density (LVD) was positive in 59.0% of the cases with aggressive morphology, while the LVD positive rate of indolent lymphoma was only 28.6% (P=0.039). Both COX-2 and VEGF-C were correlated with lymphangiogenesis (P=0.030 and 0.000, respectively). The expression levels of COX-2 and VEGF-C were significantly correlated (P=0.015). LVD, COX-2 and VEGF-C were not correlated with the gender, age, lactate dehydrogenase (LDH) levels, β2 microglobulin (β2M) levels, extranodal involvement, disease stage, B symptoms or international prognostic index of the patients. In conclusion, lymphangiogenesis was correlated with aggressive histology in NHL. COX-2 and VEGF-C are inducers of lymphangiogenesis and their expression levels were correlated in NHL.

Citing Articles

Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection.

Tan J, Fang H, Hu X, Yue M, Yang J Front Mol Biosci. 2024; 11:1476080.

PMID: 39633986 PMC: 11614729. DOI: 10.3389/fmolb.2024.1476080.

Elevated serum beta-2 microglobulin level predicts short-term poor prognosis of patients with acute omicron variant COVID-19 infection.

Gong S, Ma R, Zhu T, Ge X, Xie R, Tao Q Front Cell Infect Microbiol. 2023; 13:1204326.

PMID: 37520437 PMC: 10373586. DOI: 10.3389/fcimb.2023.1204326.

Podoplanin as a Predictive Marker for Identification of High-Risk Mycosis Fungoides Patients: An Immunohistochemical Study.

El-Ashmawy A, Shamloula M, Elfar N Indian J Dermatol. 2021; 65(6):500-505.

PMID: 33487706 PMC: 7810069. DOI: 10.4103/ijd.IJD_269_19.

B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Giagulli C, Caccuri F, Zorzan S, Bugatti A, Zani A, Filippini F Cancer Gene Ther. 2020; 28(6):649-666.

PMID: 33093643 PMC: 8203498. DOI: 10.1038/s41417-020-00246-9.

Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma.

Castro-Lopez J, Ramis A, Planellas M, Teles M, Pastor J BMC Vet Res. 2018; 14(1):158.

PMID: 29764431 PMC: 5952374. DOI: 10.1186/s12917-018-1486-0.

References

Mumprecht V, Detmar M . Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009; 13(8A):1405-16. PMC: 3572232. DOI: 10.1111/j.1582-4934.2009.00834.x. View

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

Mineo T, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B . Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004; 57(6):591-7. PMC: 1770311. DOI: 10.1136/jcp.2003.013508. View

Su J, Shih J, Yen M, Jeng Y, Chang C, Hsieh C . Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 2004; 64(2):554-64. DOI: 10.1158/0008-5472.can-03-1301. View

Ghosh N, Chaki R, Mandal V, Mandal S . COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010; 62(2):233-44. DOI: 10.1016/s1734-1140(10)70262-0. View

Detry B, Bruyere F, Erpicum C, Paupert J, Lamaye F, Maillard C . Digging deeper into lymphatic vessel formation in vitro and in vivo. BMC Cell Biol. 2011; 12:29. PMC: 3141733. DOI: 10.1186/1471-2121-12-29. View

Holopainen T, Bry M, Alitalo K, Saaristo A . Perspectives on lymphangiogenesis and angiogenesis in cancer. J Surg Oncol. 2011; 103(6):484-8. DOI: 10.1002/jso.21808. View

Karkkainen M, Haiko P, Sainio K, Partanen J, Taipale J, Petrova T . Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2003; 5(1):74-80. DOI: 10.1038/ni1013. View

Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S . Prognostic [corrected] significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res. 2009; 33(12):1627-35. DOI: 10.1016/j.leukres.2009.02.015. View

10.

Roy H, Bhardwaj S, Yla-Herttuala S . Biology of vascular endothelial growth factors. FEBS Lett. 2006; 580(12):2879-87. DOI: 10.1016/j.febslet.2006.03.087. View

11.

Wroel T, Mazur G, Dziegiel P, Jelen M, Szuba A, Kuliczkowski K . Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Folia Histochem Cytobiol. 2006; 44(1):43-7. View

12.

von Rahden B, Stein H, Puhringer F, Koch I, Langer R, Piontek G . Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res. 2005; 65(12):5038-44. DOI: 10.1158/0008-5472.CAN-04-1107. View

13.

Gratzinger D, Zhao S, Marinelli R, Kapp A, Tibshirani R, Hammer A . Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol. 2007; 170(4):1362-9. PMC: 1829468. DOI: 10.2353/ajpath.2007.060901. View

14.

Gou H, Chen X, Zhu J, Jiang M, Yang Y, Cao D . Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011; 30:14. PMC: 3037339. DOI: 10.1186/1756-9966-30-14. View

15.

Bhattacharjee R, Timoshenko A, Cai J, Lala P . Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci. 2010; 101(9):2026-32. PMC: 11159705. DOI: 10.1111/j.1349-7006.2010.01647.x. View

16.

Kyzas P, Stefanou D, Agnantis N . COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol. 2004; 18(1):153-60. DOI: 10.1038/modpathol.3800244. View

17.

Hla T, Bishop-Bailey D, Liu C, Schaefers H, Trifan O . Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999; 31(5):551-7. DOI: 10.1016/s1357-2725(98)00152-6. View

18.

Di J, Zhou J, Zhou X, Gao X, Shao C, Pang J . Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res. 2009; 40(4):268-75. DOI: 10.1016/j.arcmed.2009.03.002. View

19.

Citak E, Oguz A, Karadeniz C, Akyurek N . Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract. 2008; 204(2):89-96. DOI: 10.1016/j.prp.2007.11.005. View

20.

Lin M, Ma S, Lin H, Ji P, Xie D, Yu J . Intratumoral as well as peritumoral lymphatic vessel invasion correlates with lymph node metastasis and unfavourable outcome in colorectal cancer. Clin Exp Metastasis. 2010; 27(3):123-32. DOI: 10.1007/s10585-010-9309-0. View